Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is a biopharmaceutical company that is focused on discovering, developing and commercializing genetic medicines based on editing RNA. With a unique approach to targeting diseases through RNA editing, Korro Bio has the potential to address a significant unmet need in the treatment of rare and prevalent diseases. Its strong pipeline, including its lead program KRRO-121, has shown promising results in preclinical studies and has a clear regulatory path. With a substantial market opportunity and a differentiated product profile, Korro Bio's stock has significant potential for growth and value creation.

Bears say

Korro Bio is currently generating minimal revenue and has a highly speculative pipeline of RNA-editing therapies, which has not yet been proven through clinical trials. While the ASGCT data shows promising initial results, there is still a long road ahead to translate these findings into successful, marketable treatments. Therefore, the company's financial viability and potential success are uncertain at this time, leading to a negative outlook.

KRRO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 9 analysts, KRRO has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.